MX2023008726A - Uso de esteroides neuroactivos para el tratamiento de la disfuncion sexual. - Google Patents
Uso de esteroides neuroactivos para el tratamiento de la disfuncion sexual.Info
- Publication number
- MX2023008726A MX2023008726A MX2023008726A MX2023008726A MX2023008726A MX 2023008726 A MX2023008726 A MX 2023008726A MX 2023008726 A MX2023008726 A MX 2023008726A MX 2023008726 A MX2023008726 A MX 2023008726A MX 2023008726 A MX2023008726 A MX 2023008726A
- Authority
- MX
- Mexico
- Prior art keywords
- treatment
- sexual dysfunction
- neuroactive steroids
- patient
- neuroactive
- Prior art date
Links
- 201000001880 Sexual dysfunction Diseases 0.000 title abstract 2
- 231100000872 sexual dysfunction Toxicity 0.000 title abstract 2
- 150000003431 steroids Chemical class 0.000 title abstract 2
- 230000036299 sexual function Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163142840P | 2021-01-28 | 2021-01-28 | |
| US202163142833P | 2021-01-28 | 2021-01-28 | |
| PCT/US2022/014075 WO2022165017A1 (en) | 2021-01-28 | 2022-01-27 | Use of neuroactive steroids for treatment of sexual dysfunction |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2023008726A true MX2023008726A (es) | 2023-12-14 |
Family
ID=80787167
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023008726A MX2023008726A (es) | 2021-01-28 | 2022-01-27 | Uso de esteroides neuroactivos para el tratamiento de la disfuncion sexual. |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20240122945A1 (https=) |
| EP (1) | EP4284382A1 (https=) |
| JP (1) | JP2024507638A (https=) |
| KR (1) | KR20230136599A (https=) |
| AU (1) | AU2022214187A1 (https=) |
| CA (1) | CA3206537A1 (https=) |
| IL (1) | IL304080A (https=) |
| MX (1) | MX2023008726A (https=) |
| WO (1) | WO2022165017A1 (https=) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2882708A1 (en) | 2012-08-21 | 2014-02-27 | Sage Therapeutics, Inc. | Methods of treating epilepsy or status epilepticus |
| KR102396328B1 (ko) | 2013-04-17 | 2022-05-10 | 세이지 테라퓨틱스, 인크. | 19-노르 c3,3-이치환된 c21-n-피라졸릴 스테로이드 및 그의 사용 방법 |
| US10246482B2 (en) | 2014-06-18 | 2019-04-02 | Sage Therapeutics, Inc. | Neuroactive steroids, compositions, and uses thereof |
| JOP20200195A1 (ar) | 2014-09-08 | 2017-06-16 | Sage Therapeutics Inc | سترويدات وتركيبات نشطة عصبياً، واستخداماتها |
| WO2016082789A1 (en) | 2014-11-27 | 2016-06-02 | Sage Therapeutics, Inc. | Compositions and methods for treating cns disorders |
| EP3504189A1 (en) | 2016-08-23 | 2019-07-03 | Sage Therapeutics, Inc. | A crystalline 19-nor c3, 3-disubstituted c21-n-pyrazolyl steroid |
| MA51046A (fr) | 2017-12-08 | 2021-03-17 | Sage Therapeutics Inc | Dérivés de 21-[4-cyano-pyrazol-1-yl]-19-nor-pregan-3. alpha-ol-20-one deutérés pour le traitement de troubles du snc |
| PE20240780A1 (es) * | 2021-07-28 | 2024-04-17 | Sage Therapeutics Inc | Formas cristalinas de un esteroide neuroactivo |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EA200801081A1 (ru) * | 2005-10-14 | 2008-10-30 | Х. Лундбекк А/С | Способы лечения расстройств центральной нервной системы комбинацией малых доз эсциталопрама и бупропиона |
| KR102396328B1 (ko) | 2013-04-17 | 2022-05-10 | 세이지 테라퓨틱스, 인크. | 19-노르 c3,3-이치환된 c21-n-피라졸릴 스테로이드 및 그의 사용 방법 |
| EP3068226A4 (en) * | 2013-11-11 | 2017-05-17 | Euthymics Bioscience, Inc. | Novel methods |
| ES2805598T3 (es) | 2014-05-29 | 2021-02-12 | Sage Therapeutics Inc | Esteroides neuroactivos, composiciones y usos de los mismos |
| KR20240157128A (ko) * | 2016-03-08 | 2024-10-31 | 세이지 테라퓨틱스, 인크. | 신경활성 스테로이드, 조성물, 및 그의 용도 |
| EP3504189A1 (en) | 2016-08-23 | 2019-07-03 | Sage Therapeutics, Inc. | A crystalline 19-nor c3, 3-disubstituted c21-n-pyrazolyl steroid |
| CA3103421A1 (en) * | 2018-06-12 | 2019-12-19 | Sage Therapeutics, Inc. | A 19-nor c3,3-disubstituted c21 -n-pyrazolyl steroid and methods of use thereof |
| US20220125803A1 (en) * | 2019-03-04 | 2022-04-28 | Praxis Precision Medicines, Inc. | Methods for the treatment of perimenopause and menopause |
-
2022
- 2022-01-27 KR KR1020237025051A patent/KR20230136599A/ko active Pending
- 2022-01-27 AU AU2022214187A patent/AU2022214187A1/en active Pending
- 2022-01-27 CA CA3206537A patent/CA3206537A1/en active Pending
- 2022-01-27 US US18/263,189 patent/US20240122945A1/en active Pending
- 2022-01-27 WO PCT/US2022/014075 patent/WO2022165017A1/en not_active Ceased
- 2022-01-27 IL IL304080A patent/IL304080A/en unknown
- 2022-01-27 JP JP2023540524A patent/JP2024507638A/ja active Pending
- 2022-01-27 MX MX2023008726A patent/MX2023008726A/es unknown
- 2022-01-27 EP EP22704661.2A patent/EP4284382A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2024507638A (ja) | 2024-02-21 |
| CA3206537A1 (en) | 2022-08-04 |
| IL304080A (en) | 2023-08-01 |
| KR20230136599A (ko) | 2023-09-26 |
| AU2022214187A1 (en) | 2023-07-13 |
| US20240122945A1 (en) | 2024-04-18 |
| AU2022214187A9 (en) | 2024-05-23 |
| EP4284382A1 (en) | 2023-12-06 |
| WO2022165017A1 (en) | 2022-08-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2023008726A (es) | Uso de esteroides neuroactivos para el tratamiento de la disfuncion sexual. | |
| ZA202300875B (en) | Kat6 inhibitor methods and combinations for cancer treatment | |
| MX2020008777A (es) | Inmunoterapias relacionadas con el microbioma. | |
| MX2009011540A (es) | Tratamiento de desordenes de movimiento con el uso combinado de toxina botulinica y estimulacion del musculo. | |
| MX2011007854A (es) | Metodos para tratar infartos agudos al miocardio y trastornos relacionados. | |
| MX2025003477A (es) | Uso de reboxetina para el tratamiento de narcolepsia | |
| ZA202304965B (en) | Combination therapy for treating cancer | |
| MX361741B (es) | Tratamientos médicos a base de anamorelina. | |
| MX2019009586A (es) | Composiciones y metodos para tratar enfermedades asociadas con la permeabilidad del epitelio intestinal. | |
| MX2025000673A (es) | Metodos de administracion de nalbufina | |
| ZA202104786B (en) | Deutetrabenazine for the treatment of dyskinesia in cerebral palsy | |
| WO2019010301A8 (en) | Treatment of heart disease by inhibition of the action of muscle a-kinase anchoring protein (makap) | |
| MX2020008881A (es) | Métodos de tratamiento contra el cáncer que comprenden inhibidores de chk1. | |
| PH12022551021A1 (en) | Sequential anti-cd19 therapy | |
| MX2022012001A (es) | Tratamiento preventivo de la migra?a. | |
| MX2022004785A (es) | Metodos y composiciones para el tratamiento del sindrome de rett. | |
| ZA202002107B (en) | Use of specific sirna against protein s for the treatment of hemophilia | |
| PH12022551512A1 (en) | Synthetic processes and intermediates | |
| MX2022009081A (es) | Absorcion celular. | |
| MX2021001228A (es) | Composicion para uso en la prevencion y/o tratamiento de la mucosa genitourinaria. | |
| MA53909B1 (fr) | Compositions et méthodes de stimulation ovarienne contrôlée | |
| EP4467131A3 (en) | Microbiota restoration therapy (mrt) compositions and methods of manufacture | |
| MX2020007404A (es) | Metodos y terapia de combincion para tratar cancer. | |
| MX2019015448A (es) | Metodo para la prevencion de trombosis de desviacion de la arteria sistemica a pulmonar. | |
| MX2019004200A (es) | Terapia de combinacion. |